However, in a recent paper published in biomedicines by Drs. John and Ford, the authors challenged the notion that targeting surface ROR1 may be an effective therapy for all patients with cancers found to express ROR1 or to stain positive for ROR1 with anti-ROR1 mAbs via immunohistochemistry (IHC) [1]. The gene discussed is ROR1; the disease is cancer.